- Available therapies for psoriasis are associated with clinical efficacy according to rates of ≥75% improvement in the Psoriasis Area and Severity Index (PASI 75) at weeks 12-16 in patients aged 65 years and older.
Why this matters
- The effectiveness of psoriasis treatments in elderly patients has not previously been systematically assessed.
- Rates of PASI-75 at weeks 12-16 in patients age ≥65 years were as follows:
- 49% of methotrexate sodium users.
- 46%-52.6% of cyclosporine users.
- 27%-47.8% of acitretin users.
- 15.6%-64% of etanercept users.
- 66.7%-93% of infliximab users.
- 60.7%-65% of adalimumab users.
- 56.5% of ustekinumab users.
- 86.4% of secukinumab users.
- Older age was significantly associated with renal function deterioration in cyclosporine users (P=.03) and with lymphopenia in fumaric acid ester users (HR, 2.42; P<.001>
- 31 unique articles with 39,561 patients.
- Funding: Almirall SA; Radboud University Medical Center Nijmegen.
- Heterogeneity among included studies.
- No meta-analysis performed.
- Baseline comorbidities were often not reported.